Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

61 results about "Transdifferentiation" patented technology

Transdifferentiation, also known as lineage reprogramming, is a process in which one mature somatic cell transforms into another mature somatic cell without undergoing an intermediate pluripotent state or progenitor cell type. It is a type of metaplasia, which includes all cell fate switches, including the interconversion of stem cells. Current uses of transdifferentiation include disease modeling and drug discovery and in the future may include gene therapy and regenerative medicine. The term 'transdifferentiation' was originally coined by Selman and Kafatos in 1974 to describe a change in cell properties as cuticle producing cells became salt-secreting cells in silk moths undergoing metamorphosis.

Seawater fish cell culture fish oil and preparation method thereof

The invention belongs to the technical field of bioengineering, and particularly relates to marine fish cell culture fish oil and a preparation method thereof. The method is characterized by comprising the following steps: firstly, amplifying cells under a 2D condition, then inoculating the cells on a microcarrier for culture, carrying out adipogenic transdifferentiation induction after the cells are overgrown, and inducing for 6-8 days to realize the adipogenic transdifferentiation induction of the muscle satellite cells. According to the invention, by adjusting a lipogenic transdifferentiation culture medium and adding a lipid mixture into the culture medium, lipogenic transdifferentiation of large yellow croaker muscle satellite cells, epinephelus lanceolatus muscle cells and humpback perch muscle cells is realized by utilizing the mutual synergistic effect of various components, and cell culture large yellow croaker fish oil is prepared; a foundation is laid for further obtaining the cell culture fish meat.
Owner:OCEAN UNIV OF CHINA +1

Methods for treating prostate and lung cancer

The current disclosure is centered on the hypothesis that a better understanding of the neuroendocrine transdifferentiation (NEtD) process will provide therapeutic targets for inhibiting this transition and thus improving standard of care therapies. Accordingly, the current disclosure provides for a method for treating cancer in a subject, the method comprising administering an inhibitor of a gene, wherein the gene comprises one or more of tenascin C (TNC), advillin (AVIL), S100A7, PPARG, LOX lysyl oxidase, KLF5, APOBEC2, FOSL1, FOXM1, hedgehog, RELA, p65, IKK complex, JAK, STAT, TFAP4, geminin, OCA-1, OCA-2, Nf-kB, Nf-kB family and associated regulators, angiogenesis regulators such as BMX kinase, TEK kinase, periostin (POSTN), and VEGF family, stress genes, such as the JUN / FOS family, a gene from the S100 family, and cell state regulators such as ASCL1, POU2F3, NEUROD1, ASCL2, and YAP1.
Owner:RGT UNIV OF CALIFORNIA

Serum-free fish muscle stem cell adipogenic transdifferentiation induction method and application thereof

The invention belongs to the field of cell culture, and particularly relates to a serum-free fish muscle stem cell adipogenic transdifferentiation induction method and application thereof. Comprising a DMEM (Dulbecco Modified Eagle Medium) / F12 basal culture medium, a bovine blood extract, BMP-4 and 5-azacytidine; the invention relates to a fat-forming transdifferentiation culture medium, which comprises a DMEM / F12 culture medium, a bovine blood extract, rosiglitazone, norphytanic acid and lecithin. According to the method, the special ox blood extract is adopted, the pretreatment culture medium and the transdifferentiation culture medium are used in a combined mode, the method for rapid adipogenesis and transdifferentiation of the fish muscle stem cells under the serum-free condition is obtained, and a feasible method is provided for later large-scale production of cell culture meat.
Owner:OCEAN UNIV OF CHINA +1

Use of blocker targeting lck / fyn-mediated STAT3 phosphorylation, and use of biomaterial

The present invention provides a use of an Lck / Fyn-mediated STAT3 activation pathway as a target in the preparation or screening of a product. The product blocks the Lck / Fyn-mediated STAT3 activation pathway, inhibits differentiation of Th17 cells, and promotes transdifferentiation of the Th17 cells into Treg cells, thereby preventing or treating a Th17 cell-related immune disease. On the basis of the target, the present invention provides a use of an Lck / Fyn-mediated STAT3 activation blocker in the preparation of a product. The blocker is selected from an Lck / Fyn kinase inhibitor or a substance that specifically inhibits correct binding of Lck / Fyn and STAT3. The present invention provides a use of one or more biomaterials in the preparation of a product for preventing or treating the Th17 cell-related immune disease. The present invention also provides a drug for preventing or treating the Th17 cell-related immune disease and a treatment method thereof. Blocking Lck / Fyn-mediated STAT3 phosphorylation can be applied to the treatment of the Th17 cell-related immune disease or improvement of the capability to prevent an immune disease caused by the Th17 cells.
Owner:SUN YAT SEN UNIV

Transdifferentiation of non-dermal papilla cells to dermal papilla cells

Provided are compositions of a system and methods of use thereof to transdifferentiate non-dermal papilla (DP) cells into induced dermal papilla cells (iDPCs) and to subsequent use of these cells in the treatment of hair loss.
Owner:DNOVO INC

Method for direct transdifferentiation of somatic cell

A method of direct transdifferentiation of somatic cells into other somatic cells may be convenient and still have good reproducibility, excellent production efficiency, and short performed time. Methods for direct transdifferentiation of somatic cells into other somatic cells may include: (a) introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into other somatic cells.
Owner:JUNTENDO EDUCATIONAL FOUNDATION

Method for inducing transdifferentiation of somatic cells into mammary epithelial cells by inducing mammary epithelial cell exosome

The invention provides a method for inducing transdifferentiation of somatic cells into mammary epithelial cells by using an exosome for inducing mammary epithelial cells. The method is efficient, safe and high in specificity. The somatic cells are induced to be transdifferentiated into the mammary epithelial cells by inducing the mammary epithelial cell exosome, so that a new cell source and a new technical means are provided for repairing and regenerating mammary tissues and treating related diseases.
Owner:THE PEOPLES HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION

Energizing mesenchymal stem cell, energizing mesenchymal stem cell composition and application of energizing mesenchymal stem cell composition in regenerative medicine field

The invention belongs to the technical field of biomedicine, and particularly discloses an endowed mesenchymal stem cell, an endowed mesenchymal stem cell composition and application of the endowed mesenchymal stem cell composition to preparation of a medicine for treating organ insufficiency, and the endowed mesenchymal stem cell is obtained by treating human mesenchymal stem cells with ingenol HEP14. The energizing mesenchymal stem cell composition comprises energizing mesenchymal stem cells and HEP14 / PLGA microspheres which are prepared by adopting a polylactic acid-glycolic acid copolymer (PLGA) as a carrier and have high HEP14 loading capacity and long-acting HEP14 slow release. The energized mesenchymal stem cell has the effects of enhancing the survival activity and dryness of the mesenchymal stem cell, resisting tissue fibrosis, promoting tissue angiogenesis, and promoting tissue regeneration and functional recovery; the endowed mesenchymal stem cells and the HEP14 / PLGA microspheres are used in a combined manner, and the retention and transdifferentiation effects of the endowed mesenchymal stem cells in tissues are enhanced, so that the functions of the endowed mesenchymal stem cells and the application of the endowed mesenchymal stem cells in the field of regenerative medicine are further enhanced.
Owner:BLOOM BIOTECHNOLOGY CO LTD (SHENZHEN)

Auto-loaded vesicular cancer therapy platform derived from induced neural stem cells

An extracellular vesicle based therapeutic compound for treating tumors and cancers. The extracellular vesicle based therapeutics use exosomes that are transdifferentiation-derived induced neural stem cells (Exo-iNSCs) that produce an extracellular vesicle having a tumoricidal gene product or an anti-cancer molecule withing the extracellular vesicle. The therapeutic agent is present in a lumen of the extracellular vesicle or is distributed across a membrane surface of the extracellular vesicle. Methods of using the extracellular vesicle based therapeutic compounds are effective in treating tumors and cancers.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Serum-free culture medium and application thereof in obtaining nerve cells by transdifferentiation of embryo fibroblasts

The invention belongs to the technical field of biology, and discloses a serum-free culture medium and application thereof in obtaining nerve cells through embryo fibroblast transdifferentiation. The serum-free culture medium consists of a basic culture medium, a protein additive and cell culture auxiliary components, the protein additive consists of transferrin, a leukemia inhibition factor and a basic fibroblast growth factor; the final concentration of the transferrin is 5 ng / mL-30 ng / mL, the final concentration of the leukemia inhibition factor is 50 ng / mL-150 ng / mL, and the final concentration of the basic fibroblast growth factor is 10 ng / mL-25 ng / mL. The serum-free culture medium can promote the conversion speed of transdifferentiation of fibroblasts into nerve cells, can significantly improve the transdifferentiation efficiency, and can improve the cell survival rate of transdifferentiation of mouse embryo fibroblasts into nerve cells.
Owner:CENTRE FOR REGENERATIVE MEDICINE & HEALTH HONG KONG INSTITUTE OF SCIENCE & INNOVATION CHINESE ACADEMY OF SCIENCES

A method for preparing a cell-derived extracellular matrix and a cell-derived extracellular matrix-coated cell culture plate and applications thereof

The present application belongs to the field of biomedical technology, and particularly relates to a cell-derived extracellular matrix and a preparation method and application of a cell culture plate coated with the cell-derived extracellular matrix. The present application cultures human astrocytes in a cell culture plate, and makes the human astrocytes secrete extracellular matrix. After the human astrocytes are added into a cell lysate for cell removal treatment, nucleic acid fragmentation treatment is performed to obtain the cell-derived extracellular matrix. The present application has relatively simple operation, short time period, and can realize batch production of extracellular matrix without external virus carrying and stable components. The obtained cell-derived extracellular matrix is resistant to storage, has good stability, is highly similar to a natural brain environment when coated on a cell culture plate, has good biocompatibility with cells, can be applied to tissue repair and regeneration as an ideal biomedical material, can regulate the progress and efficiency of human dermal fibroblast HDF transdifferentiation into neurons, and can obtain in-vitro survival neurons.
Owner:UNIV OF ELECTRONICS SCI & TECH OF CHINA

Application of Olig2 in transdifferentiation of astrocytes into functional neurons

ActiveCN119639671AWith electrophysiological functionpromotes transdifferentiationNervous system cellsFermentationOLIG2Transdifferentiation
The invention belongs to the technical field of biology, and particularly discloses application of Olig2 in transdifferentiation of astrocytes into functional neurons, and the application provided by the invention realizes overexpression of neurogenesis promoting transcription factors and knock-down of induced hindering factors. The overexpression of neurogenesis promoting transcription factors and the knock-down of induced hinders are expected to become an effective method for improving the transdifferentiation efficiency and generating more new neurons, so that the method can be widely applied to the treatment of various nervous system diseases related to neuron loss, such as neurodegenerative diseases, central nervous system traumatic diseases and the like.
Owner:JINAN UNIVERSITY

Direct transdifferentiation for the treatment of neurological diseases

RE1 / NRSE blockers are used for treating nervous system diseases. This disclosure relates to the field of biomedicine. More specifically, this disclosure relates to the use of RE1 / NRSE elements as targets for transdifferentiating non-neuronal cells into neuronal cells; and the use of RE1 / NRSE blockers in preventing and / or treating diseases associated with neuronal loss or death. This disclosure provides methods for blocking RE1 / NRSE elements to regulate the expression of neuron-related genes in non-neuronal cells, which include reducing the binding of REST to RE1 / NRSE elements, or reducing the amount or activity of REST. This disclosure also provides RE1 / NRSE element blockers, especially the binding domains of endogenous RE1 / NRSE-binding proteins and their variants, which can be used for preventing and / or treating diseases associated with neuronal loss or death.
Owner:SHANGHAI GENEMAGIC BIOSCIENCES CO LTD

Use of acadvl in preparation of drugs for preventing and treating chronic kidney disease complicated with vascular calcification

PendingCN123078623ADiseaseTransdifferentiation
This invention discloses the application of ACADVL in the preparation of drugs for the prevention and treatment of vascular calcification in chronic kidney disease (CKD), belonging to the field of biomedical technology. The key technical points are: clinical tissue sample analysis revealed a significant downregulation of ACADVL expression in the radial artery tissue of CKD patients with vascular calcification; in vitro cell experiments confirmed that overexpression of ACADVL can inhibit high-phosphorus-induced vascular smooth muscle cell calcification, reduce alizarin red-stained calcified nodules and intracellular calcium content, and reverse the transdifferentiation of vascular smooth muscle cells into osteoblast-like phenotypes by upregulating the expression of the contractile phenotype marker protein SM22α. This invention is the first to apply ACADVL to the prevention and treatment of vascular calcification in CKD, providing a new drug target and candidate molecule for the clinical treatment of this disease.
Owner:SHUNDE HOSPITAL SOUTHERN MEDICAL UNIV (THE FIRST PEOPLES HOSPITAL OF SHUNDE FOSHAN)

Methods for the treatment of cancer

Combination therapies for the treatment of cancers are provided. In some aspects, a nucleic acid encoding a transdifferentiation determinant is administered in combination with a chemotherapeutic, electric fields therapy (e.g., TTField), or electromagnetic fields therapy to synergistically treat a cancer such as a glioma or glioblastoma (GBM).
Owner:UNIV OF SOUTHERN CALIFORNIA

Method for direct transdifferentiation of somatic cell

PendingUS20260185053A1TransdifferentiationGene product
Provided is a method for production by direct transdifferentiation of somatic cells into another somatic cells which is convenient, has good reproducibility, is excellent in production efficiency, and is performed in a short period of time. The method for production by direct transdifferentiation of somatic cells into another somatic cells comprises: (a) a step of introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) a step of culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into another somatic cells.
Owner:JUNTENDO EDUCATIONAL FOUNDATION

Methods for transdifferentiation of in vitro purified limbal stem cells into lens spherules

The present application provides a method for in vitro purified corneal limbal stem cells to be transdifferentiated into lens spherules, specifically, the present application inoculates corneal limbal stem cells onto a culture plate containing a Matrigel glue layer, and cultures the corneal limbal stem cells in a culture system containing Y-27632 additives in LSCM culture solution, so that lens spherule organoids can be obtained. The method of the present application can realize the rapid transdifferentiation of corneal limbal stem cells into lens spherules, so that they can be implanted into the capsular bag as seed cells for in situ regeneration of the lens.
Owner:ZHEJIANG UNIV

miRNA REPROGRAMMING OF SMOOTH MUSCLE CELLS INTO ENDOTHELIAL CELLS

Described herein is a panel of three or four miRNAs that can be used to transdifferentiate vascular smooth muscle cells or fibroblasts into endothelial cells. As demonstrated herein, miR-143-3p and / or miR-145-5p inhibitors coupled with miR-5 146a-5p and miR-18lb-5p mimics were sufficient for accomplishing this transformation. This transdifferentiation protocol can be used to generate inducible endothelial cells that are transcriptionally, phenotypically, and functionally similar to other endothelial cells. This miRNA-engineered approach is useful in a range of cardiovascular-based therapies. In some embodiments, the methods use a 4-miRNA consisting of miR-143-3p and / or miR-145-Sp inhibitors, and miR-146a-5p and miR-181b-5p mimics, to produce iECs from SMCs or fibroblasts. In some embodiments, the SMC are isolated from aorta, coronary artery, pulmonary artery, umbilical artery, bladder smooth muscle cells, or derived from adipose tissue smooth muscle cells or progenitors, or blood derived circulating smooth muscle cell progenitors.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Si-RNA composition for inducing cardiac fibroblasts to transdifferentiate into endothelial cells and application of si-RNA composition

The invention relates to the field of biological medicine, in particular to a si-RNA composition for inducing cardiac fibroblasts to transdifferentiate into endothelial cells and application of the si-RNA composition. The si-RNA composition comprises a si-RNA (Ribonucleic Acid) aiming at a gene Huwe1, a si-RNA aiming at a gene Ltbp3, a si-RNA aiming at a gene Dysf and a si-RNA aiming at a gene Hivep3. The HLDH (Huwe1, Ltbp3, Dysf and Hive3) combined knockout can be used for successfully inducing the transformation of fibroblasts into endothelial cells in an in-vitro ischemia and hypoxia state. A carrier containing shRNA capable of expressing and generating the si-RNA composition is delivered into the heart, so that cardiac fibroblasts undergo transdifferentiation in vivo and participate in angiogenesis, and therefore, increase of fibrosis area and adverse ventricular remodeling after myocardial ischemia are limited through ways such as fibrosis remodeling, the heart function is retained, and myocardial ischemia is improved and repaired.
Owner:THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV

Application of small molecule medicine composition in transdifferentiation of glioma cells

PendingCN120478397ANervous disorderNervous system cellsTransdifferentiationGlioblastoma cell line
The invention discloses an application of a small molecular medicine composition in transdifferentiation of glioma cells. The small molecular medicine composition comprises LiCl, Pirfenidone, Forskolin and RO4929097, and the small molecular medicine composition comprises LiCl, Pirfenidone, Forskolin and RO4929097. The invention further discloses application of the small molecule medicine composition in treating glioma, preparing a medicine for treating glioma and preparing a medicine for inducing glioma cells to be transdifferentiated into neuron-like cells. According to the present invention, with the application of the small molecule drug combination, the glioblastoma line U251 can be induced into the neuron-like cells, the tumor proliferation and the subcutaneous tumor formation ability can be inhibited, and the median lifetime of the xenotransplantation brain glioma model mouse can be prolonged.
Owner:JINAN UNIVERSITY

Functional feline pancreatic cells from adipose tissue

Compositions and methods are described herein for transdifferentiation of multipotent stromal cells into cells that can express insulin.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE

Methods for efficient generation of GABAergic interneurons from pluripotent stem cells

Enhanced methods for the generation of medial ganglionic eminence (MGE) cells from pluripotent stem cells are provided that involve an additional step of contacting the cells with an activator of FGF8 signaling while differentiating Pax6+ cells progenitor cells into MGE cells with an activator of sonic hedgehog, and optionally a Wnt inhibitor. The activator of FGF8 signaling shifts the differentiation of the population of cells to NKX2.1+ MGE cells, rather than to CopuTFII+ caudal ganglionic eminence (CGE) cells. Methods for treatment of neurological disorders, such as epilepsy, by transplant of MGE cells, or GABAergic interneurons derived from human pluripotent stem cells, into a subject in need of treatment are also provided. Human pluripotent stem cell derived MGE cells when transplanted successfully suppress spontaneous seizures, e.g. in epilepsy. We also have developed a method to purify MGE cells and maturing interneurons from differentiated pluripotent stem cells using cell surface marker and molecular beacon technology.
Owner:THE MCLEAN HOSPITAL CORP

Agent for glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue

To provide novel factors involved in cancer cell proliferation, invasion, metastasis and the like, by the interact of CAFs and cancer cells.SOLUTION: Provided is an inhibitor for glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue, and an inhibitor of the invasiveness and metastasis of cancer tissue, containing a FOXQ1 inhibitor as an active ingredient.SELECTED DRAWING: None
Owner:JUNTENDO EDUCATIONAL FOUNDATION

Use of olig2 in transdifferentiation of astrocytes into functional neurons

The application belongs to the technical field of biotechnology, and specifically discloses application of Olig2 in transdifferentiation of astrocytes into functional neurons, and provides overexpression of a neurogenesis-promoting transcription factor and knockdown of an inducible hindering factor, which are expected to be effective methods for improving transdifferentiation efficiency and generating more newborn neurons, and thus are widely applied to treatment of various nervous system diseases related to neuron loss, such as neurodegenerative diseases and traumatic diseases of the central nervous system.
Owner:JINAN UNIVERSITY

Biomarker combination for detecting hypertrophic scars, kits and uses thereof

This invention discloses a combination of biomarkers, a kit, and their applications for detecting hypertrophic scars (HTS). The biomarker combination includes a core biomarker and / or auxiliary biomarker 1 and / or auxiliary biomarker 2; the core biomarker is ABCC9 and CSPG4, auxiliary biomarker 1 is RGS5 and ACTA2, and auxiliary biomarker 2 is PDGFRB and TRPC6. This invention also provides a kit containing the above biomarker combination detection reagents and a drug screening method. This invention reveals for the first time that pathological pericytes are the core fibrotic cells in HTS, breaking through the traditional understanding that fibroblasts are the dominant cells. By targeting and inhibiting the abnormal activation, proliferation, and transdifferentiation of pericytes into myofibroblasts, the generation of myofibroblasts and matrix deposition are curbed at the source, providing a new strategy for precision treatment of HTS. Compared with traditional therapies, this approach has higher specificity and can achieve early molecular warning and quantitative detection of trace tissues for HTS, effectively overcoming the lag and subjectivity of clinical morphological diagnosis.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Transdifferentiation of non-hair follicle stem cells to non-auditory induced hair follicle stem cells

Provided are compositions of a system and methods of use thereof to transdifferentiate non-hair follicle stem (HFS) cells into non-auditory induced hair follicle stem cells (iHFSCs) and to subsequent use of these cells in the treatment of hair loss.
Owner:DNOVO INC

Use of transdifferentiation of glial cells into neurons in prevention or treatment of diseases associated with neuron loss-of-function or death

The transdifferentiation of glial cells into neurons is useful for prevention or treatment of a disease associated with loss of function or death. The present disclosure relates to the field of biomedicines. More specifically, the present disclosure relates to use of a REST inhibitor in the treatment of a disease associated with loss of function or death of neurons. The present disclosure can effectively induce transdifferentiation of astrocytes into dopamine neurons by inhibiting the expression, content or activity of a gene of REST or an RNA thereof or an encoding protein thereof in astrocytes in the brain, and can effectively induce transdifferentiation of Müller glia (MG) into retinal ganglion cells (RGCs) or photoreceptor cells by inhibiting the expression, content or activity of the gene of REST or the RNA thereof or the encoding protein thereof in the retina, thereby preventing and / or treating the disease associated with loss of function or death of neurons.
Owner:SHANGHAI GENEMAGIC BIOSCIENCES CO LTD

Induction medium for inducing transdifferentiation of fibroblasts into nucleus pulposus cells and application of induction medium

The invention discloses an induction culture medium for inducing fibroblasts to transdifferentiate into nucleus pulposus cells and application of the induction culture medium, and belongs to the technical field of cytobiology and regenerative medicine. The induction culture medium comprises a basic culture medium and an induction composition, can be used for realizing 2D / 3D transdifferentiation of fibroblasts into nucleus pulposus cells, and meets the requirements of different application scenes. Meanwhile, the invention further provides an amplification culture medium, a technical system for forming a 3D (three-dimensional) organoid through amplification of the amplification culture medium is provided, and the method has important significance in promoting cell therapy of the intervertebral disc degenerative change.
Owner:FIBROX THERAPEUTICS (SHANGHAI) CO LTD

In vivo reprogramming of photoreceptor cells

The invention relates to in vivo methods and compositions for converting one cell type to another cell type. In particular, the invention relates to transdifferentiation of a cell to a photoreceptor cell, preferably a rod photoreceptor cell. In one aspect, the invention provides an in vivo method for reprogramming a source cell, the method comprising increasing the protein expression of one or more transcription factors, or biologically active fragments or variants thereof, in the source cell, wherein the source cell is reprogrammed to exhibit at least one characteristic of a target cell, wherein the source cell is a glial cell, the target cell is a photoreceptor cell; and the transcription factors are one or more of those selected from ASCLI, NEURODI, NRL, NR2E3, RAX, RORB, OTX2, CRX and PAX6.
Owner:CENT FOR EYE RES AUSTRALIA

Transdifferentiation of Pancreatic Duct Cells Into Beta-Like Cells

PendingUS20250144152A1Metabolism disorderHydrolasesTransdifferentiationAldehyde Dehydrogenase Family
This disclosure relates to methods of inducing insulin production from pancreatic duct cells in response to glucose or transdifferentiating pancreatic duct cells into insulin-producing beta-like cells by administering an agent that inhibits aldehyde dehydrogenase family 3 member B2 (ALDH3B2) protein or an agent that inhibits the expression of ALDH3B2 gene. This disclosure also relates to methods of treatment of diabetes by administering an agent that inhibits ALDH3B2 protein or an agent that inhibits the expression of ALDH3B2 gene.
Owner:JOSLIN DIABETES CENTER INC